Join

or

Existing user? Login

Medicines shortages

Government issues first serious shortage protocols to combat shortages of fluoxetine

The Department of Health and Social Care has introduced measures to allow pharmacists to supply alternative strengths of the drug without ing a patient’s prescriber.

Fluoxetine blister pack

Source: Algis Motuza / Alamy Stock Photo

The serious shortage protocols will be in place for as long as manufacturing issues lead to shortages of some 10mg, 30mg and 40mg fluoxetine capsules

The government has issued the first serious shortage protocols (SSP) to combat shortages of the antidepressant fluoxetine.

The SSPs, issued on 3 October 2019, allow pharmacists to supply alternative strengths or pharmaceutical forms of fluoxetine without having to consult a patient’s prescriber, with immediate effect.

The measures have been put in place following news that manufacturing issues have resulted in shortages of some fluoxetine 10mg, 30mg and 40mg capsules. It has been estimated that some of these stocks will not be available until early December 2019. .

Legislation came into force on 1 July 2019 that introduced a pharmacist’s ability to dispense against a protocol instead of a prescription, without going back to the prescriber first, as a measure to combat medicines shortages. This protocol was drawn up by a team of senior pharmacists and doctors, including Keith Ridge, the chief pharmaceutical officer for England.

The SSPs will remain in place for as long as manufacturing issues mean the drug is in short supply, to help alleviate pressure on the supply chain. 

Sandra Gidley, president of the Royal Electronicjuice, welcomed the announcement: “If a pharmacist can sort out a patient’s requirements from existing stock it will save a lot of time and this can only be good news for patients,” she said, adding that fluoxetine substitutions were fairly straightforward to carry out. 

The government has also announced restrictions on exporting of 19 hormone replacement therapy (HRT) products to tackle shortages. Several HRT products manufactured by Resource Medical, Themex and Mylan will soon be out of stock, with some not expected to be available until mid-2020.

The restrictions will also prevent medicine wholesalers from parallel exporting — where companies buy medicines meant for UK patients and sell on for a higher price in another country.

“These shortage problems have been in existence for more than ten years,” said Gidley. “Although they are worse now than ever, the prime consideration must be patients — anything the government can do to ensure they get their medicines is welcomed.” 

Exporting restrictions have also been brought in for a further five medicines, including all adrenaline auto-injectors and hepatitis B vaccines, which have also been in short supply.

Announcing the measures in a press release, the Department of Health and Social Care (DHSC) said the use of the SSPs and the export ban were unrelated to Brexit, but added that SSPs and exporting restrictions “provide the DHSC with additional tools to our robust, multi-layered preparations for exiting the EU”.

Rick Greville, director of supply chain at the Association of the British Pharmaceutical Industry, said the precautionary measures would be “welcomed” by its members, who have been asked by the government to maintain rolling six-week stockpiles of medicines in case of a no-deal Brexit.

“[These measures] mean that these stockpiles of medicines that companies have built over previous months are better protected and available for use only by the NHS patients for which they were intended,” he said.

Martin Sawer, executive director of the Healthcare Distribution Association (HDA), which represents wholesalers, said its member companies believed that a small number of firms that hold a Wholesale Dealer Licence (WDL) may be buying small amounts of stock from a number of locations and then exporting aggregated packs of these medicines.

Sawer said the HDA was calling on the Medicines and Healthcare products Regulatory Agency to consider a “more rigorous and transparent enforcement” of the obligations on all WDL holders in line with good distribution practice (GDP) legislation.

GDP legislation includes an obligation on WDL holders to ensure an “appropriate and continued supply of such relevant medicinal products to pharmacies and persons who may lawfully sell such products … so that the needs of patients in the UK are covered”.

Matt Hancock, the health secretary, said that people should be “fully reassured” that the government would always act to ensure that there was an adequate supply of the medicines needed by patients. 

  • This article was amended on 3 October 2019 to reflect that three serious shortage protocols were introduced by the DHSC to help deal with fluoxetine shortages.

Citation: Electronicjuice DOI: 10.1211/PJ.2019.20207142

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Pharmaceutical Statistics

    This book on basic statistics has been specifically written for pharmacy students.

    £33.00
  • Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00
  • Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00
  • Pharmaceutical Isolators

    £27.00
  • Essentials of Economic Evaluation in Healthcare

    An introduction to economic evaluation specific to healthcare, for those with little or no knowledge of economics. Covers cost effectiveness, cost utility and cost benefit analysis.

    £33.00

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.